Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxymetazoline + ketamine
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intranasal, Topical, Oral, Intravenous, Intramuscular
01
Overview
**Oxymetazoline + ketamine** is a theoretical or compounded combination of two pharmaceuticals: oxymetazoline, a direct-acting alpha-adrenergic agonist primarily used as a topical decongestant and vasoconstrictor, and ketamine, a dissociative anesthetic that acts mainly as an NMDA receptor antagonist with additional effects on opioid and other receptors. There is no evidence of a marketed fixed-dose combination product with this exact pairing, but both drugs may be co-administered in clinical practice (for example, in certain procedural settings). If coadministered, synergy may occur due to additive effects on blood pressure and heart rate. The main clinical relevance of this combination relates to enhanced cardiovascular stimulation and the need for monitoring, rather than a uniquely developed drug indication or formulation[1][6][7][9].
- Other names
- oxymetazoline + ketamine
02
Targets
ADRA2C (α2C)ADRA1A (α1A)ADRA2A (α2A)NMDAR (Glutamate receptor ionotropic, NMDA)ADRB2 (β2)ADRA2B (α2B)
Beyond the preview
Go deeper on oxymetazoline + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxymetazoline + ketamine.